shire map
Select a
Location

Shire Global

Pipeline

Note: The pipeline programs listed below do not include those from the recent combination with Baxalta. These programs will be added in the future.

Our Pipeline

Click on each of the items below for more information
and to sort columns on the right by Phase.

PRECLINICAL

Phase I

Phase I/II

Phase II

Phase II/III

Phase III

REGISTRATION

SHP465: ADHD

Phase III

Therapeutic Area: CNS

Type of Molecule: Small Molecule

SHP555: (US) Chronic Constipation

Phase III

Therapeutic Area: GI / Metabolic / Endocrine

Type of Molecule: Small Molecule

SHP606: Dry Eye Disease

Registration

Therapeutic Area: Ophthalmics

Type of Molecule: Small Molecule

Learn more at ShireTrials.com Click Here

SHP607: Prevention of ROP

Phase II

Therapeutic Area: Ophthalmics

Type of Molecule: Protein

Learn more at ShireTrials.com Click Here

SHP608: Dystrophic Epidermolysis Bullosa

Preclinical

Therapeutic Area: Renal / Fibrotic

Type of Molecule: Protein

SHP609: Hunter IT

Phase II III

Therapeutic Area: CNS / Neuromuscular

Type of Molecule: Enzyme

Learn more at ShireTrials.com Click Here

SHP610: Sanfilippo A

Phase II

Therapeutic Area: CNS / Neuromuscular

Type of Molecule: Enzyme

Learn more at ShireTrials.com Click Here

SHP611: MLD

Phase I II

Therapeutic Area: CNS / Neuromuscular

Type of Molecule: Enzyme

Learn more at ShireTrials.com Click Here

SHP616: Acute Antibody Mediated Rejection

Phase II

Therapeutic Area: Complement Biology

Type of Molecule: Protein

SHP616: Acute Neuromyelitis Optica

Phase I

Therapeutic Area: Complement Biology

Type of Molecule: Protein

SHP616: (Japan) HAE Prophylaxis

Phase III

Therapeutic Area: Complement Biology

Type of Molecule: Protein

SHP616: HAE Prophylaxis

Phase I

Therapeutic Area: Complement Biology

Type of Molecule: Protein

SHP620: CMV in transplant patients

Phase II

Therapeutic Area: Renal / Fibrotic

Type of Molecule: Small Molecule

SHP621: Eosinophilic Esophagitis (EoE)

Phase II

Therapeutic Area: GI / Metabolic / Endocrine

Type of Molecule: Small Molecule

SHP622: Friedreich’s Ataxia

Phase I

Therapeutic Area: CNS / Neuromuscular

Type of Molecule: Small molecule

SHP623: (rC1-INH) HAE Prophylaxis

Preclinical

Therapeutic Area: Compliment Biology

Type of Molecule: Protein Replacement

SHP625: Alagille Syndrome

Phase II

Therapeutic Area: GI / Metabolic / Endocrine

Type of Molecule: Small Molecule

SHP625: Primary Biliary Cirrhosis

Phase II

Therapeutic Area: GI / Metabolic / Endocrine

Type of Molecule: Small Molecule

SHP625: Primary Sclerosis Cholangitis

Phase II

Therapeutic Area: GI / Metabolic / Endocrine

Type of Molecule: Small Molecule

SHP625: Progressive Familial Intrahepatic Cholestasis

Phase II

Therapeutic Area: GI / Metabolic / Endocrine

Type of Molecule: Small Molecule

SHP626: Non-Alcoholic Steatohepatitis

Phase I

Therapeutic Area: GI / Metabolic / Endocrine

Type of Molecule: Small Molecule

Learn more at ShireTrials.com Click Here

SHP627: Focal Segmental Glomerulosclerosis

Phase I

Therapeutic Area: Renal / Fibrotic

Type of Molecule: Small Molecule

SHP630: Autosomal Dominant Retinitis Pigmentosa (adRP)

Preclinical

Therapeutic Area: Ophthalmics

Type of Molecule: Small Molecule

SHP631: Hunter Syndrome

Phase I

Therapeutic Area: CNS / Neuromuscular

Type of Molecule: Enzyme

SHP636: MRT for Cystic Fibrosis

Preclinical

Therapeutic Area: GI/Metabolic/Endocrine

Type of Molecule: mRNA Replacement

SHP637: MRT for UCD

Preclinical

Therapeutic Area: Renal/Fibrotic

Type of Molecule: mRNA Replacement

SHP639: Glaucoma

Preclinical

Therapeutic Area: Ophthalmics

Type of Molecule: Peptide

SHP640: (FST-100) Infectious Conjunctivitis

Phase II

Therapeutic Area: Ophthalmics

Type of Molecule: Small Molecule

guanfacine: (EU) ADHD

Registration

Therapeutic Area: CNS

Type of Molecule: Small Molecule

guanfacine: (Japan) ADHD

Phase III

Therapeutic Area: CNS

Type of Molecule: Small Molecule

icatibant: (Japan) HAE

Phase III

Therapeutic Area: Complement Biology

Type of Molecule: Peptide

Learn more at ShireTrials.com Click Here

lisdexamfetamine dimesylate: (Japan) ADHD

Phase II

Therapeutic Area: CNS

Type of Molecule: Small Molecule

NATPAR: (EU) Hypoparathyroidism

Registration

Therapeutic Area: GI / Metabolic / Endocrine

Type of Molecule: Protein

TH/GCH1: GenePod Parkinson's Subset

Preclinical

Therapeutic Area: CNS / Neuromuscular

Type of Molecule: Gene Therapy

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our cookie notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE